Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AndroMETa 118 phase 2 master protocol of telisotuzumab adizutecan combinations in pancreatic and biliary tract cancers
MOH_2026-06-25_016900Phase 2Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of telisotuzumab adizutecan in pancreatic cancer (PC) and biliary cancer (3 arms), sponsored by AbbVie Inc. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
pancreatic cancer (PC)biliary cancer
Beyond the preview
Go deeper on MOH_2026-06-25_016900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-06-25_016900.